Many People With Schizophrenia Have Stable Cognition Over 20 Years
By Lori Solomon HealthDay Reporter
THURSDAY, Feb. 15, 2024 -- There are varying cognitive trajectories over 20 years among individuals with schizophrenia spectrum disorders, according to a study published online Feb. 12 in Psychological Medicine.
Marie Starzer, M.D., from the Copenhagen Research Center for Mental Health and the University of Copenhagen in Denmark, and colleagues assessed whether cognitive deficits progress over time in individuals with schizophrenia. The analysis included 20-year follow-up of 156 participants from the OPUS I trial.
The researchers found that 30.5 percent of patients had a declining course of neurocognition, 49.2 percent had a stable course of neurocognition, and 20.3 percent experienced improvements in neurocognition. At the 20-year follow-up, good cognitive functioning was significantly associated with higher levels of social functioning. Increasing experiential negative symptoms at follow-up were significantly correlated to cognitive worsening. Declining neurocognition was predicted by younger age at inclusion and a low level of education (less than 10 years).
"Our findings support the notion of different schizophrenia subtypes with varying trajectories," the authors write. "Neurocognitive impairment at the 20-year follow-up was associated with other poor outcomes, highlighting the importance of treatments aimed at improving neurocognition in patients with schizophrenia spectrum disorders."
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted February 2024
Read this next
AI-Assisted Contours Superior to Cognitively Defined Prostate Cancer Contours
WEDNESDAY, July 3, 2024 -- Artificial intelligence (AI)-assisted definition of prostate cancer contours reduces underestimation of the extent of prostate cancer, according to a...
Mean Cost of Bringing New Drug to U.S. Market Is $879.3 Million
TUESDAY, July 2, 2024 -- The mean cost of developing a new drug for the U.S. market is estimated to be $879.3 million when both drug development failure and capital costs are...
Patient–Primary Care Provider Language Concordance Tied to Better Outcomes
TUESDAY, July 2, 2024 -- Patient-family physician language concordance is associated with a lower risk for adverse outcomes, according to a study published online June 3...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.